Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Polaris Group, an AssemblyTM Health company providing staffing and consulting solutions for long-term care communities, today announced its...
Polaris Group, a leading post-acute healthcare consulting and staffing company, launches Polaris Edge to help communities navigate ongoing regulatory ...
The Centers for Medicare & Medicaid Services (CMS) released a memorandum on Thursday, September 17 that requires Nursing Homes to permit access to...
Polaris Group, a biopharmaceutical company focused on developing novel drugs for cancer, announced that Chi Van Dang, M.D., Ph.D. has joined its...
Polaris Pharmaceuticals, Inc. (a subsidiary of Polaris Group), a biopharmaceutical company focused on developing novel drugs for cancer, announced...
Polaris Group, a biopharmaceutical company focused on developing novel drugs for cancer, announced results from a phase 1 clinical study that...
At the American Society Clinical Oncology's 2018 annual meeting, scientists from National Institute of Cancer Research Taiwan reported results from a ...
Polaris Group announced results from a phase 1 clinical study, showing that Polaris lead therapeutic candidate ADI-PEG 20 in combination with FOLFOX...
Polaris Group announced today that the first patient has been dosed in a phase 2 trial of ADI-PEG 20 in combination with gemcitabine and docetaxel...
Polaris Group announced that it has signed a multiyear strategic Collaboration Agreement with MD Anderson Cancer Center to utilize its Immunotherapy...
Polaris Group announced today that ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, can selectively enhance the effect of...
Polaris Group announced today that ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, can boost anti-tumor immune surveillance...
Polaris Group announced today that FLT-PET scan provided early evidence of response to arginine depletion by its lead therapeutic ADI-PEG 20...
Polaris Group announced today that the phase III study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care...
Polaris Group announced today results from an ongoing phase 1b study conducted at Memorial Sloan Kettering Cancer Center that tests combining ADI-PEG ...
Polaris Group announced today that ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, is a potential salvage therapy for BRAF...
Polaris Group announced today the preliminary results from an ongoing phase 1 study that tests combining its lead therapeutic ADI-PEG 20 (pegylated...
Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with folinic acid (leucovorin), ...
Polaris Group announced today that its lead product candidate ADI-PEG 20 (pegylated arginine deiminase) has received orphan drug designation for the...
Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with sorafenib, a current first ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.